Collaboration - April 30, 2019
AstraZeneca starts artificial intelligence collaboration
AstraZeneca and BenevolentAI has began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF). Scientists from the two organisations will work side-by-side to combine AstraZeneca’s genomics, chemistry and clinical data with BenevolentAI’s target identification platform […]
Collaboration - April 23, 2019
Novo Nordisk and Gilead Sciences initiate collaboration
The two companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (NASH). The intended clinical trial will be a proof-of-concept study combining Novo Nordisk’s semaglutide (GLP-1 analogue) and Gilead’s cilofexor (FXR agonist) and firsocostat (ACC inhibitor) for the treatment of patients with NASH. The companies are also […]
Collaboration - April 10, 2019
The Spring issue of our magazine is out now!
Don’t forget to subscribe to our magazine and read inspiring interviews, in-depth stories and articles about the Nordic life science industry’s progress and challenges. This issue is for example filled with inspiring articles about scientists and business leaders, including the new CEO of AstraZeneca Sweden, Katarina Ageborg, and LEO Pharma’s admired CEO, Gitte Aabo. We […]
Clinical Trials - April 5, 2019
LEO Pharma initiates clinical trial of microarray patches for psoriasis treatment
Together with LTS Lohmann Therapie-Systeme the company will start the first-ever clinical trial of microarray patches for the local intradermal treatment of psoriasis. The study will start in April 2019 with expected completion later this year and the aim of the study is to document safety and efficacy in patients. Microarray patch A microarray patch […]
Collaboration - March 29, 2019
AstraZeneca and Daiichi Sankyo enter collaboration
The global development and commercialization collaboration agreement with Daiichi Sankyo is for trastuzumab deruxtecan (DS-8201), a antibody-drug conjugate (ADC) and potential new targeted medicine for cancer treatment. Trastuzumab deruxtecan is currently in development for the treatment of multiple HER2-expressing cancers, including breast and gastric cancer, and in patients with HER2-low expression. In 2017, trastuzumab deruxtecan was granted […]
Collaboration - March 20, 2019
Pilloxa in strategic partnership with Bayer
Swedish Pilloxa is initiating a collaboration with the Scandinavian branch of Bayer and get the opportunity to introduce more people to their smart pillbox through Bayer’s network, both in Scandinavia and globally. “We see great potential in this innovation. For someone not too familiar in the subject it might seem like a trivial task to take […]
